Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | MLNR | O43193 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AOX1 | Q06278 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.92 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | PGR | P06401 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | DRD1 | P21728 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL13697563 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL15472911 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL17119502 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL2328474 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13105406 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13900514 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL24415240 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL14342511 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13930075 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL20833993 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 143797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144896-A1 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | SIREN BIOTECHNOLOGY, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122081121-A | Preparation method and application of athlete-source bifidobacterium probiotics for intestinal barrier repair | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079427-A | Method for degrading organic pollutants by coupling nano-confinement catalytic membrane with micro-nano bubbles | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075680-A | Milk exosome-loaded erythromycin nano-preparation and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-117384932-B | Expression vector pHH40 and application thereof in construction of wine coccus engineering bacteria | QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES) (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122071676-A | Lactobacillus delbrueckii subspecies bulgaricus with ester aroma and taste of fermented yoghourt and application thereof | 内蒙古伊利实业集团股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260137644-A1 | COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER | XMK THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | US | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4001388-A | POLYESTERS | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | claimed |
| US-4000263-A | STORAGE STABILITY, PROPYLENE GLYCOL, ETHYL ALCOHOL, ETHOXYLATED LAURYL ALCOHOL | WESTWOOD PHARMACEUTICALS, INC. (US) | 1976-12-28 | — | — | US | claimed |
| US-3991203-A | Vehicle composition containing 1-substituted azacyclopentan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-11-09 | — | — | US | claimed |
| US-3989815-A | PENETRATION OF SKINS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-11-02 | — | — | US | claimed |
| US-3989816-A | PENETRATION OF SKINS OR MEMBRANES | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-11-02 | — | — | US | claimed |
| US-3983209-A | HYDROPHOBIC BIOERODIBLE POLYMER, MICROBIOCIDE OR PROTEOLYTIC ENZYME | ALZA CORPORATION (US) | 1976-09-28 | — | — | US | claimed |
| US-3979511-A | ERYTHROMYCINS | ABBOTT LABORATORIES (US) | 1976-09-07 | — | — | US | claimed |
| US-3963579-A | Microbiological process for the production of pepstatins | SANRAKU-OCEAN CO., LTD. (JA) | 1976-06-15 | — | — | US | claimed |
| US-3960757-A | HYDROPHOBIC | TOYO JOZO CO., LTD. (JA) | 1976-06-01 | — | — | US | claimed |